Learning objectives
- To understand the prevalence of coexisting cardiovascular and kidney disease
- To provide guidance on detecting cardiovascular or kidney disease, and when to refer such patients for specialist care
- To describe the similarities and differences between guidelines on the management of cardiovascular and kidney disease
- To discuss the role of pharmacological treatment options in reducing both cardiovascular and renal risk
Speakers
Jemima Scott, NIHR Doctoral Research Fellow and Specialty Trainee in renal medicine, University of Bristol and North Bristol NHS Trust
Chris Gale, Professor of Cardiovascular Medicine and Honorary Consultant Cardiologist, University of Leeds and Leeds Teaching Hospitals NHS Trust
Learning module instructions
This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning).
Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value.
After you have successfully completed the test you will be able to download your certificate.
Quiz Summary
0 of 5 Questions completed
Questions:
Information
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
Results
Results
0 of 5 Questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Categories
- Not categorized 0%
- 1
- 2
- 3
- 4
- 5
- Current
- Review
- Answered
- Correct
- Incorrect
-
Question 1 of 5
1. Question
1. What proportion of people with advanced kidney disease (KDIGO stage G4 or G5) have coexisting cardiovascular disease?
CorrectIncorrect -
Question 2 of 5
2. Question
2. According to current NICE guidelines, what is the blood pressure target for patients with a urinary albumin to creatinine ratio (UACR) >70 mg/mmol?
CorrectIncorrect -
Question 3 of 5
3. Question
3. Which of the ‘four pillars’ of heart failure therapy (beta-blockers, mineralocorticoid receptor antagonists [MRAs], angiotensin receptor-neprilysin inhibitors [ARNIs], or sodium-glucose cotransporter 2 [SGLT2] inhibitors) are contraindicated in patients with an estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m2?
CorrectIncorrect -
Question 4 of 5
4. Question
4. Which of the following is true regarding the relationship between kidney disease and low-density lipoprotein cholesterol (LDL-C)?
CorrectIncorrect -
Question 5 of 5
5. Question
5. What is the current NICE guidance regarding statin therapy for secondary cardiovascular prevention in people with chronic kidney disease and an eGFR >30 mL/min/1.73 m2?
CorrectIncorrect